Biotech firm Terray Therapeutics lands $120m Series B

The capital infusion will be used to progress internal programs into clinical trials and further enhance Terray’s integrated AI platform, tNova.

17 October 2024•1 min read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.

Deals & Exits Briefs